Topoisomerase I inhibitors: Review and update

Annals of Oncology

Volumn 8, Issue 9, 1997, Pages 837-855

  Rothenberg, M L ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Camptothecin analogues; Cancer; CPT 11; Irinotecan; Topoisomerase I inhibitors; Topotecan

Indexed keywords

4 [5 (4 METHYL 1 PIPERAZINYL)[2,5' BI 1H BENZIMIDAZOL] 2' YL]PHENOL; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; 9 AMINOCAMPTOTHECIN; ANTHRAQUINONE DERIVATIVE; BULGAREIN; CAMPTOTHECIN; CAMPTOTHECIN DERIVATIVE; CARBAZOLE DERIVATIVE; CISPLATIN; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; EPIBERBERINE; EXATECAN; FAGARONINE; FLUOROURACIL; FOLINIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; HOE 33342; INDOLE DERIVATIVE; IRINOTECAN; LURTOTECAN; MUTANT PROTEIN; PACLITAXEL; PLANT EXTRACT; RUBITECAN; SAINTOPIN; TOPOTECAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE; VINDESINE;

ALOPECIA; ANIMAL CELL; BONE MARROW SUPPRESSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MIXTURE; DRUG SOLUBILITY; FATIGUE; HUMAN; HUMAN CELL; INTRAARTERIAL DRUG ADMINISTRATION; LIVER TOXICITY; MOUSE; MULTIDRUG RESISTANCE; NAUSEA; NEUTROPENIA; NONHUMAN; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SOLID TUMOR; THROMBOCYTOPENIA; VOMITING;

ANIMALS; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; CLINICAL TRIALS; DNA TOPOISOMERASES, TYPE I; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; HUMANS; TOPOTECAN;

EID: 0030826929     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008270717294     Document Type: Review

References (249)

1. Wang JC. DNA topoisomerases. Annu Rev Biochem 1985; 54: 665-97.
2. Wall ME, Wani MC, Cooke CE et al. Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumour inhibitor from Camptotheca acuminata. J Am Chem Soc 1966; 88: 3888-90.
3. Eng W-K, Faucette L, Johnson RK et al. Evidence that DNA topoisomerase I is necessary for the cytotoxic effects of camptothecin. Mol Pharmacol 1988; 34: 755-60.
4. Chen AY, Liu LF. Mechanisms of resistance to topoisomerase inhibitors. Cancer Treat Res 1994; 73: 263-81.
5. Morris EJ, Geller HM. Induction of neuronal apoptosis by camptothecin, an inhibitor of DNA topoisomerase I: Evidence for cell cycle-independent toxicity. J Cell Biol 1996; 134: 757-70.
6. Shimizu T, Pommier Y. DNA fragmentation induced by protease activation in p53-null human leukemia HL60 cells undergoing apoptosis following treatment with the topoisomerase I inhibitor camptothecin: Cell-free system studies. Exp Cell Res 1996; 226: 292-301.
7. Gottlieb JA, Guarino AM, Call JB et al. Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC 100880). Cancer Chemother Rep 1970; 54: 461-70.
8. Muggia FM, Creven PJ, Hansen HH et al. Phase I clinical trial of weekly and daily treatment with camptothecin (NSC 100880). Cancer Chemother Rep 1972; 56: 515-21.
9. Moertel CG, Schutt AJ, Reitemeier RJ et al. Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer. Cancer Chemother Rep 1972; 56: 95-101.
10. Bleiberg H, Rothenberg ML (eds). CPT-11: From DNA topology to clinical activity. Semin Oncol 1996; 23 (Supp 1): 1-50.
11. Verweij J. Initial and disease-oriented clinical research of topotecan. The fifth conference on DNA topoisomerases in therapy, 1994 (Abstr 30).
12. Dahut W, Harold N, Takimoto C et al. Phase I and pharmacokinetic study of 9-aminocamptothecin given as a 72-hour infusion in adult cancer patients. J Clin Oncol 1996; 14: 1236-44.
13. Arbuck SG, Takimoto C. 9-Aminocamptothecin. The sixth conference on DNA topoisomerases in therapy, 1995 (Abstr S36a).
14. Wissel P, Verweij J, Eckardt J et al. On-going phase I trials of intravenous GI 147211, a totally synthetic camptothecin analogue, administered daily × 5 and 72 hour CI regimens. The fifth conference on DNA topoisomerases in therapy, 1994 (Abstr 33).
15. Paz-Ares L. Overview of the phase I trials with G1 147211. The sixth conference on DNA topoisomerases in therapy, 1995 (Abstr S36).
16. Kunimoto T, Nitto K, Tanako T et al. Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonoxy-camptothecin, a novel water soluble derivative of camptothecin, against murine tumours. Cancer Res 1987; 47: 5944-7.
17. Tsuruo T, Matsuzaki T, Matsushita M et al. Antitumour effect of CPT-11, a new derivative of camptothecin against pleiotropic drug resistant tumour in vitro and in vivo. Cancer Chemother Pharmacol 1988; 21: 71-4.
18. Slichenmeyer WJ, Von Hoff DD. New natural products in cancer chemotherapy. J Clin Pharmacol 1990; 30: 770-88.
19. Bissery MC, Mathieu-Boué A, Lavelle F. Preclinical evaluation of CPT-11, a camptothecin derivative. Proc Am Assoc Cancer Res 1991; 32: 402 (Abstr).
20. Bissery MC, Mathieu-Boué A, Lavelle F. Experimental antitumour activity of CPT-11 in vitro and in vivo. Proc 7th NCI-EORTC Symposium on New Drugs in Cancer Therapy, Amsterdam 1992; 82 (Abstr).
21. Johnson RK, McCabe FL, Faucette LF et al. SKF 104864, a water soluble analog of camptothecin with a broad spectrum of activity in preclinical models. Proc Am Assoc Cancer Res 1989; 30: 623 (Abstr).
22. Johnson RK, McCabe FL, Gallagher G et al. Comparative efficacy of topotecan irinotecan and of 9-aminocamptothecin in preclinical tumour models. Ann Oncol 1992; 3 (Suppl 1): 85 (Abstr).
23. Kingsbury WD, Boehm JC, Jakas DR et al. Synthesis of water soluble (aminoalkyl) camptothecin analogues: Inhibition of topoisomerase I and antitumor activity. J Med Chem 1991; 34: 98-107.
24. Vassal G, Terrier-Lacombe MJ, Bissery MC et al. Therapeutic activity of CPT-11, a DNA-topoisomerase I inhibitor, against peripheral neuroectodermal tumour and neuroblastoma xenografts. Br J Cancer 1996; 74: 537-45.
25. Burris HA III, Hanauske A-R, Johnson RK et al. Activity of topotecan, a new topoisomerase I inhibitor, against human tumour colony-forming units in vitro. J Natl Cancer Inst 1992; 84: 1816-20.
26. Shimada Y, Rothenberg M, Hilsenbeck SG et al. Activity of CPT-11 (irinotecan hydrochloride), a topoisomerase I inhibitor, against human tumour colony-forming units. Anti-Cancer Drugs 1994; 5: 202-6.
27. Tanizawa A, Fujimori A, Fujimori Y, Pommier Y. Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials. J Natl Cancer Inst 1994; 86: 836-42.
28. Madden KR, Champoux JJ. Over-expression of human topoisomerase I in baby hamster kidney cells: Hypersensitivity of clonal isolates to camptothecin. Cancer Res 1992; 52: 525-32.
29. Sugimoto Y,Tsukahara S, Oh-Hara T et al. Decreased expression of DNA topoisomerase I in camptothecin-resistant tumour cell lines as determined by monoclonal antibody. Cancer Res 1990; 50: 6925-30.
30. Bjornsti M-A, Benedetti P, Vigilianti GA, Wang JC. Expression of human DNA topoisomerase I in yeast cells lacking yeast DNA topoisomerase I: Restoration of sensitivity of the cells to the antitumor drug camptothecin. Cancer Res 1989; 49: 6318-23.
31. McLeod HL, Keith WN. Variation in topoisomerase I gene copy number as a mechanism for intrinsic drug sensitivity. Br J Cancer 1996; 74: 508-12.
32. Giovanella BC, Stehlin JS, Wall ME et al. DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science 1989; 246: 1046-8.
33. Husain I, Mohler JL, Seigler HF, Besterman JM. Elevation of topoisomerase I messenger RNA, protein, and catalytic activity in human tumours: Demonstration of tumour-type specificity and implications for cancer chemotherapy. Cancer Res 1994; 54: 539-46.
34. van der Zee AGJ, Hollema H, de Jong S et al. P-glycoprotein expression and DNA topoisomerase I and II activity in benign tumours of the ovary and malignant tumours of the ovary, before and after platinum/cyclophosphamide chemotherapy. Cancer Res 1991; 51: 5915-20.
35. Hirabayashi N, Kim R, Nishiyama M et al. Tissue expression of topoisomerase I and II in digestive tract cancers and adjacent normal tissues. Proc Am Soc Cancer Res 1992; 33: 436 (Abstr).
36. Chen AY, Yu C, Potmesil M et al. Camptothecin overcomes MDR 1-mediated resistance in human KB carcinoma cells. Cancer Res 1991; 51: 6039-44.
37. Mattern MR, Hoffmann GA, Polsky RM et al. In vitro and in vivo effects of clinically important camptothecin analogues on multidrug-resistant cells. Oncol Res 1993; 5 (12): 467-74.
38. Gupta E, Lestingi TM, Mick R et al. Metabolic fate of irinotecan in humans: Correlation of glucuronidation with diarrhoea. Cancer Res 1994; 54: 3723-5.
39. Lokiec F, Canal P, Gay C et al. Pharmacokinetics of irinotecan and its metabolites in human blood, bile, urine. Cancer Chemother Pharmacol 1995; 36: 79-82.
40. Lokiec F, Monegier FU, Sorbier B, Sanderink G-J. Irinotecan (CPT-11) metabolites in human bile and urine. Clin Cancer Res 1996; 2: 1943-9.
41. Abigerges D, Chabot GG, Armand JP et al. Phase I and pharmacologic studies of the camptothecin analogue irinotecan administered every three weeks in cancer patients. J Clin Oncol 1995; 13: 210-21.
42. Rothenberg ML, Kuhn JG, Burris HA et al. Phase I and pharmacokinetic trial of weekly CPT-11. J Clin Oncol 1993; 11: 2194-204.
43. Chabot GG, Abigerges D, Catimel G et al. Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials. Ann Oncol 1995; 6: 141-51.
44. Rothenberg ML, Eckardt JR, Kuhn JG et al. A phase II trial of irinotecan (CPT-11)in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol 1996; 14: 1128-35.
45. One Y, Sasaki Y, Shinkai T et al. Brief communication: Phase I study and pharmacokinetics of CPT-11 with 5-day continuous infusion. J Natl Cancer Inst 1992; 84: 972-4.
46. Herben V, Schellens J, Swart M et al. Phase I and pharmacokinetic study of irinotecan (CPT11) with a prolonged (14D) infusion schedule. Proc Am Soc Clin Oncol 1997; 16: 201a (Abstr 705).
47. Van Groeningen CJ, Van der Vijgh WJF, Giaccone G et al. Phase I clinical and pharmacokinetic study of 5 day CPT-11 hepatic arterial infusion chemotherapy. Proc Am Soc Clin Oncol 1997; 16: 219a (Abstr 768).
48. Drengler R, Burris H, Dietz A et al. A phase I trial to evaluate orally administered irinotecan HCL (CPT-11) given daily × 5 every 3 weeks in patients with refractory malignancies. Proc Am Soc Clin Oncol 1996; 15: 489 (Abstr 1560).
49. Negoro S, Fukuoka M, Niitani H et al. A phase II study of CPT-11. a camptothecin derivative, in patients with primary lung cancer. Jpn J Cancer Chemother 1991; 18: 1013-9.
50. De Forni M, Bugat R, Chabot GG et al. Phase I and pharmacokinetic study of the camptothecin derivative irinotecan administered on a weekly schedule in cancer patients. Cancer Res 1994; 54: 4347-54.
51. Taguchi T, Wakui A, Hasegawa K et al. Phase I clinical study of CPT-11. Jpn J Cancer Chemother 1990; 17: 115-20.
52. Rowinsky EK, Grochow LB, Ettinger DS et al. Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-{4-(1-piperidino)-carbonyloxycamptothecine} (CPT-11) administered as a ninety-minute infusion every 3 weeks. Cancer Res 1994; 54: 427-36.
53. Catimel G, Chabot GG, Guastalla JP et al. Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for 3 consecutive days every 3 weeks in patients with advanced solid tumours. Ann Oncol 1995; 6: 133-40.
54. Burris HA, Rothenberg ML, Kuhn JG, Von Hoff DD. Clinical trials with topoisomerase I inhibitors. Semin Oncol 1992; 19: 663-9.
55. SugiyamaT, Takeuchi S, Yakushiji M. Phase I study of irinotecan (CPT-11) in combination with cisplatin (CDDP) on cervical carcinoma. Proc Am Soc Clin Oncol 1994; 13: 856 (Abstr).
56. Masuda N, Fukuoka M, Kudoh S et al. Phase I and pharmacologic study of irinotecan in combination with cisplatin for advanced lung cancer. Br J Cancer 1993; 68: 777-82.
57. Masuda N, Fukuoka M, Kudoh S et al. Phase I study of irinotecan and cisplatin with granulocyte colony-stimulating factor support for advanced non-small-cell lung cancer. J Clin Oncol 1994; 12: 90-6.
58. Mori K, Suga U, Kishiro I et al. A phase I study of CPT-11 and cisplatin (5-day continuous infusion) for advanced non-small-cell lung cancer. Proc Am Soc Clin Oncol 1994; 13: 1234 (Abstr).
59. Kudoh S, Fukuoka M, Masuda N et al. Relationship between CPT-11 pharmacokinetics and diarrhoea in the combination chemotherapy of irinotecan (CPT-11) and cisplatin (CDDP). Proc Am Soc Clin Oncol 1993; 12: 364 (Abstr).
60. Shinkai T, Arioka H, Kunikane H et al. Phase I clinical trial of irinotecan (CPT-11), 7-ethyl-10-{4-(1-piperidino)-lpiperidino} carbonyloxy-camptothecine, and cisplatin in combination with fixed dose of vindesine in advanced small cell lung cancer. Cancer Res 1994; 54: 2636-42.
61. Karato A, Sasaki Y, Shiraishi J et al. Pharmacokinetic study in the dose escalation study of CPT-11 and VP-16. Proc Am Assoc Cancer Res 1993; 34: 2325 (Abstr).
62. Masuda N, Fukuoka M, Kuoh S et al. Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer. J Clin Oncol 1994; 12: 1833-41.
63. Karato A, Sasaki Y, Shinkai T et al. Phase I study of CPT-11 and etoposide in patients with refractory solid tumours. J Clin Oncol 1993; 11: 2030-5.
64. Negoro S, Fukuoka M, Masuda N et al. Phase I study of irinotecan (CPT-11) and etoposide with G-CSF in advanced lung cancer. Proc Am Soc Clin Oncol 1993; 12: 133 (Abstr 331).
65. Oshita F, Kazumasa N, Nishivaki Y et al. Phase II study of irinotecan and etoposide in patients with metastatic non-small-cell lung cancer. J Clin Oncol 1997; 15: 304-9.
66. Shimada Y, Sasaki Y, Sugano K et al. Combination phase I study of CPT-11 (irinotecan) combined with continuous infusion of 5-fluorouracil (5-FU) in metastatic colorectal cancer. Proc Am Soc Clin Oncol 1993; 12: 575 (Abstr).
67. Rixe O, Benhamouda A, Farabos C et al. A phase I study of concomitant CPT-11 and 5-FU combination in preliminary results. 8th European Conference on Clinical Oncology and Cancer Nursing (ECCO), Paris, 29 Oct -2 Nov 1995.
68. Saltz LB, Kanowitz J, Kemeny NE et al. Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil and leucovorin in patients with advanced solid tumours. J Clin Oncol 1996; 14: 2959-67.
69. Houghton JA, Cheshire PJ, Hallman JD II et al. Evaluation of irinotecan in combination with 5-fluorouracil or etoposide in xenograft models of colon adenocarcinoma and rhabdomyosarcoma. Clin Cancer Res 1996; 2: 107-18.
70. Sasaki Y, Ohtsu A, Shimada Y et al. Simultaneous administration of CPT-11 and fluorouracil: Alteration of the pharmacokinetics of CPT-11 and SN-38 in patients with advanced colorectal cancer. J Natl Cancer Inst 1994; 86: 1096-8.
71. Shimada Y. Topoisomerase I inhibitors: Combination chemotherapy with CPT-11 in gastrointestinal cancers. 2nd International Conference on Biology, Prevention, and Treatment of Gastrointestinal Malignancies, Cologne, 9-12 Jan 1995; 37 (Abstr).
72. Mans DRA, Brondani de Rocha A, Gricivich I et al. The cytotoxicity of the irinotecan (CPT-11)-5-fluorouracil combination in human colon carcinoma cell line is sequence dependent. Ann Oncol 1996: 7 (Suppl 5): 9 (Abstr 36).
73. Harstrick A, Schleucher N, Vanhoefer U et al. Cytotoxic interactions of SN-38, the active metabolite of irinotecan, and 5-FU or tomudex in 5-FU sensitive and 5-FU resistant colorectal carcinoma cell lines. Ann Oncol 1996; 7 (Suppl 5): 5 (Abstr 13).
74. Shimada Y, Yoshino M, Wakui A et al. Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. J Clin Oncol 1993; 11: 909-13.
75. Rougier P, Bugat R, Douillard JY et al. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 1997; 15: 251-60.
76. Van Cutsem E, Cunningham D, Ten Bokkel Huinink W et al. CPT-11 in 5-FU-resistant colorectal cancer: Patient benefit. Eur Soc Med Oncol Symposium, Vienna, Nov 2-5, 1996.
77. Pitot HC, Wender D, O'Connell MJ et al. A phase II trial of CPT-11 (irinotecan) in patients with metastatic colorectal carcinoma: A North Central Cancer Treatment Group (NCCTG) study. Proc Am Soc Clin Oncol 1994; 13: (Abstr 573).
78. Conti JA, Kemeny NE, Saltz LB et al. Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol 1996; 14: 709-15.
79. Rothenberg ML, Pazdur R, Rowinsky EK et al. A phase II multicenter trial of alternating cycles of irinotecan and 5-FU/ LV in patients with previously untreated metastatic colorectal cancer. Proc Am Soc Clin Oncol 1997; 16: 266a (Abstr 944).
80. Barone C, Pozzo C, Starkhammar H et al. CPT-11 alternating with 5-fluorouracil/folinic acid: A multicentre phase II study in first-line chemotherapy of metastatic colorectal cancer. Proc Am Soc Clin Oncol 1997; 16: 270a (Abstr 957).
81. Vanhoefer U, Harstrick A, Muller C et al. Phase I study of a weekly schedule of irinotecan in combination with high-dose foliic acid and 5-fluorouracil as first-line chemotherapy in patients with advanced colorectal cancer. Proc Am Soc Clin Oncol 1997; 16: 272a (Abstr 967).
82. Ducreux M, Rougier P, Ychou M et al. Phase I/II study of escalating dose of CPT-11 in combination with LV5FU2 ('De Gramont' regimen) every two weeks in the treatment of colorectal cancer. Proc Am Soc Clin Oncol 1997; 16: 234a (Abstr 823).
83. Douillard JY, Ibrahim N, Riviere A et al. Phase II study of CPT-11 (irinotecan) in non-small-cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 1995; 14: 365.
84. Depierre A, Lemarie E, Quoix E et al. Phase II study with CPT-11 (irinotecan) in non-small-cell lung cancer. Bull Cancer 1994; 81: 563 (Abstr).
85. Fukuoka M, Niitani H, Suzuki A et al. A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J Clin Oncol 1992; 10: 16-20.
86. Negoro S, Fukuoka M, Masuda N et al. Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer. J Natl Cancer Inst 1991; 83: 1164-8.
87. Baker L, Khan R, Lynch T et al. Phase II study of irinotecan (CPT-11) in advanced non-small-cell lung cancer. Proc Am Soc Clin Oncol 1997; 16: 461a (Abstr 1658).
88. Masuda N, Fukuoka M, Kusunoki Y et al. CPT-11: A new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 1992; 10: 1225-9.
89. Le Chevalier T, Ibrahim N, Chomy P et al. A phase II study of irinotecan (CPT-11) in patients with small cell lung cancer progressing after initial response to first-line chemotherapy. Proc Am Soc Clin Oncol 1997; 16: 450a (Abstr 1617).
90. Wagener DJT, Verdonk HER, Dirix LY et al. Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC Early Clinical Trials Group study. Ann Oncol 1995; 6: 129-32.
91. Sakata Y, Shimada Y, Yoshino M et al. A late phase II study of CPT-11, irinotecan hydrochloride, in patients with advanced pancreatic cancer. Jpn J Cancer Chemother 1994; 21: 1039-46.
92. Chevallier B, Nhome C, Dieras Vet al. Phase II trial of CPT-11 in advanced cervical carcinoma. Proc Am Soc Clin Oncol 1995; 14: (Abstr 737).
93. Verschraegen CF, Levy T, Kudelka AP et al. Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix. J Clin Oncol 1997; 15: 625-31.
94. Takeuchi S, Noda K, Yakushiji M. Late phase II study of CPT-11, a topoisomerase I inhibitor, in advanced cervical carcinoma. Proc Am Soc Clin Oncol 1992; 11: 224 (Abstr 708).
95. Potkul RK, Price FC, Bailey H et al. Irinotecan (CPT-11) in advanced squamous cell carcinoma of the cervix (Phase II). Proc Am Soc Clin Oncol 1995; 14 (Abstr 785).
96. Futatsuki K, Wakui A, Nakao I et al. Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. Jpn J Cancer Chemother 1994; 21: 1033-8.
97. Taguchi T, Tominaga T, Ogawa M et al. A late phase II study of CPT-11 (irinotecan) in advanced breast cancer. Jpn J Cancer Chemother 1994; 21: 1017-24.
98. Bonneterre J, Pion JM, Adenis A et al. A phase II study of a new camptothecinanalog CPT-11 in previously treated advanced breast cancer patients. Proc Am Soc Clin Oncol 1993; 12: (Abstr 179).
99. Ikeda S, Ishihara K, Ohura T et al. Late phase II study of irinotecan (CPT-11) in squamous carcinoma of the skin and malignant melanoma. Skin Cancer 1993; 8: 503-13.
100. Umesaki N, Takeuchi S, Noda K et al. The clinical effect of CPT-11, a new topoisomerase I inhibitor, against uterine cervical and ovarian cancers. 5th World Conference on Clinical Pharmacology and Therapeutics, 25 July 1992 (Abstr).
101. Sugiyama T, Nishida T, Ookura N et al. Is CPT-11 useful as a salvage chemotherapy for recurrent ovarian cancer? Proc Am Soc Clin Oncol 1997; 16: 378a (Abstr 1347).
102. Nagao K, Fukuoka M, Kuriyama T, Niitani H. A phase II study of irinotecan combined with cisplatin in non-small-cell lung cancer. Recent Adv Chemother 1993; 872-3.
103. DeVore R, Crawford J, Dimery I et al. Phase II trial of irinotecan (CPT-11) plus cisplatin in advanced NSCLC. Proc Am Soc Clin Oncol 1997; 16: 466a (Abstr 1674).
104. Mori K, Hirose T, Tominaga K. Phase II study of irinotecan and infusional cisplatin with recombinant human granulocyte colony-stimulating factor support in the treatment of advanced non-small-cell lung cancer. Proc Am Soc Clin Oncol 1997; 16: 476a (Abstr 1714).
105. Okamoto H, Nagatomo A, Kunitoh H et al. A combination phase I-II study of carboplatin/irinotecan plus 0-CSF with the Calvert equation in patients with advanced non-small-cell lung cancer. Proc Am Soc Clin Oncol 1995; 14: (Abstr 1150).
106. Fujiwara Y, Yamakido M, Fukuoka M et al. Phase II study of irinotecan (CPT-11)and cisplatin (CDDP) in patients with small-cell lung cancer (SCLC). Proc Am Soc Clin Oncol 1994; 13: 335 (Abstr 1110).
107. Shirao K, Shimada Y, Kondo H et al. Phase I-II study of irinotecan hydrochloride combined with cisplatin in patients with advanced gastric cancer. J Clin Oncol 1997; 15: 921-7.
108. Boku N, Ohtsu A, Shimada Y et al. Phase II study of a combination of CDDP and CPT-11 in metastatic gastric cancer: CPT-11 study group for gastric cancer. Proc Am Soc Clin Oncol 1997; 16: 264a (Abstr 936).
109. Shimuzu Y, Umezawa S. Combination of CPT-11 with MMC is active for clear cell carcinoma of the ovary. Can J Infect Dis 1995; 6 (Suppl C): 292C (Abstr 0674).
110. Saotome T, Takagi T, Kumagai K et al. Combination chemotherapy with irinotecan and adriamycin for refractory or relapsed malignant lymphoma: A pilot study. Ann Oncol 1996; 7 (Suppl 5): 113 (Abstr 540).
111. 2 irinotecan given every two weeks. Proc Am Soc Clin Oncol 1997; 16: 268a (Abstr 953).
112. Von Hoff DD, Rothenberg ML, Pitot HC et al. Irinotecan (CPT-11) therapy for patients with previously treated metastatic colorectal cancer: Overall results of PDA-reviewed pivotal trials. Proc Am Soc Clin Oncol 1997; 16: 228a (Abstr 803).
113. Ikuno N, Soda H, Watanabe M, Oka M. Irinotecan (CPT-11) and characteristic mucosal changes in the mouse ileum and cecum. J Natl Cancer Inst 1995; 87: 1876-83.
114. Hagipantelli R, Saliba F, Misset JL et al. Pathophysiology and therapy of irinotecan (CPT-11) induced delayed diarrhoea. A prospective assessment. Proc Am Soc Clin Oncol 1995; 14: (Abstr 1499).
115. Droz JP, Marty M, Douillard JY et al. CPT-11 in 5-FU-resistant colorectal cancer: Management of delayed diarrhoea. Ann Oncol 1996; 7 (Supp 5): 48 (Abstr 223).
116. Mick R, Gupta E, Vokes EE et al. Limited-sampling models for irinotecan pharmacokinetics - pharmacodynamics: Prediction of biliary index and intestinal toxicity. J Clin Oncol 1996; 14: 2012-9.
117. Rivory LP, Riou JF, Haaz M-C et al. Identification and properties of a major plasma metabolite of irinotecan (CPT-11) isolated from the plasma of patients. Cancer Res 1996; 56: 3689-94.
118. Lestingi TM, Yokes EE, Gray W et al. A phase I trial of CPT-11 in solid tumours with G-CSF and antidiarrheal support. Proc Am Soc Clin Oncol 1995; 14: 480 (Abstr 1563).
119. Tamura K, Takada M, Masuda N, Fukuoka M. Radiosensitization effect of CPT-11 against human lung tumour xenografts. Proc Am Assoc Cancer Res 1995; 36: 605 (Abstr 3599).
120. Saka H, Shimokata K, Yoshida S et al. for the JCOG-Lung Cancer Study Group. Irinotecan (CPT-11) and concurrent radiotherapy in locally advanced non-small-cell lung cancer: A phase II study of Japan Clinical Oncology Group (JCOG9504). Proc Am Soc Clin Oncol 1997; 16: 447a (Abstr 1607).
121. Sirott MN, Saltz L, Young C et al. Phase I trial and pharmacologic study of intravenous topotecan. Proc Am Soc Clin Oncol 1991; 10: 104 (Abstr).
122. Rowinsky EK, Grochow LB, Hendricks CB et al. Phase I and pharmacologic study of topotecan: A novel topoisomerase I inhibitor. J Clin Oncol 1992; 10: 647-56.
123. ten Bokkel Huinink WW, Rodenhuis S, Beijnen J et al. Phase I study of the topoisomerase inhibitor topotecan (SK&F 104864-A). Proc Am Soc Clin Oncol 1992; 11: 110 (Abstr).
124. Cole D, Blaney S, Balis F et al. A phase I and pharmacokinetic study of topotecan in pediatric patients. Proc Am Soc Clin Oncol 1992; 11: 116 (Abstr).
125. Beijnen JH. Clinical pharmacokinetics and pharmacodynamics of topotecan. The sixth conference on DNA topoisomerases in therapy, Amsterdam, 6-8 September 1995 (Abstr S37).
126. Wall J, Burris H, Rodriguez G et al. Phase I trial of topotecan (SK&F 10464) in patients with refractory solid tumours. Proc Am Soc Clin Oncol 1991; 10: 98 (Abstr).
127. Verweij J, Lund B, Beignen J et al. Phase I and pharmacokinetic study of topotecan: A new topoisomerase I inhibitor. Ann Oncol 1993; 4: 673-78.
128. Saltz L, Sirott M, Young C et al. Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumours, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor. J Natl Cancer Inst 1993; 85: 1499-507.
129. Haas N, LaCreta F, Walczak J et al. Phase I/pharmacokinetic study of topotecan by 24-hour continuous infusion. Cancer Res 1994; 54: 1220-1226.
130. Abbruzzese JL, Madden T, Sugarman SM et al. Phase I clinical and plasma and cellular pharmacological study of topotecan without and with granulocyte colony-stimulating factor. Clin Cancer Res 1996; 2: 1489-97.
131. Pratt CB, Stewart C, Santana VM et al. Phase I study of topotecan for pediatric patients with malignant solid tumours. J Clin Oncol 1994; 12: 539-43.
132. Rowinsky EK, Adjei A, Ross C et al. Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia. J Clin Oncol 1994; 12: 2193-203.
133. Hochster H, Liebes L, Speyer J et al. Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well tolerated regimen. J Clin Oncol 1994; 12: 553-9.
134. Creemers GJ, Schellens JHM, Planting ASTh et al. Cumulative myelosuppression of topotecan (T) administered as a 21-days continuous infusion in patients with colorectal cancer. Proc Am Soc Clin Oncol 1995; 14: (Abstr 354).
135. Gerrits CJH, Burris H, Schellens JHM et al. Five days of once daily topotecan, a phase I and pharmacologic study in adults. Ann Oncol 1996; 7 (Suppl 5): 124 (Abstr 597).
136. Burris H, Gerrits CJH, Schellens JHM et al. Oral topotecan for 10 days once daily and twice daily every three weeks: A phase I and pharmacologic study in adults. Ann Oncol 1996; 7 (Suppl 5): 126 (Abstr 605).
137. Furman WL, Baker SD, Pratt CB et al. Escalating systemic exposure of continuous infusion topotecan in children with recurrent acute leukemia. J Clin Oncol 1996; 14: 1504-11.
138. Armstrong D, Rowinsky E, Donehower R et al. A phase II trial of topotecan as salvage therapy in epithelial ovarian cancer. Proc Am Soc Clin Oncol 1995; 14: 275 (Abstr 769).
139. Kudelka AJ, Tresukosol D, Edwards CL et al. Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. J Clin Oncol 1996; 14: 1552-7.
140. Creemers GJ, Bolis G, Gore M et al. Topotecan, an active drug in the second line treatment of epithelial ovarian cancer: Results of a large European phase II study. J Clin Oncol 1996; 14: 3056-61.
141. ten Bokkel Huinink W, Gore M, Carmichael J et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 1997; 15: 2183-93.
142. Bolis G, Malstrom H, Mangioni C et al. Efficacy of topotecan in advanced epithelial ovarian cancer after failure of platinum and paclitaxel: International Topotecan Study Group trial. Ann Oncol 1996; 7 (Suppl 5): 68 (Abstr 321).
143. Schiller JH, Kim K, Hutson P et al. Phase II study of topotecan in patients with extensive-stage small cell carcinoma of the lung: An Eastern Cooperative Oncology Group trial. J Clin Oncol 1996; 14: 2345-52.
144. Perez-Soler R, Glisson BS, Lee JS et al. Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan. J Clin Oncol 1996; 14: 2785-90.
145. Ardizzoni A, Hansen H, Dombernowsky P et al. for the European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: A phase II study in patients with refractory and sensitive disease. J Clin Oncol 1997; 15: 2090-6.
146. Eckardt J, Gralla R, Palmer MC et al. Topotecan as second-line therapy in patients with small cell lung cancer: A phase II study. Ann Oncol 1996; 7 (Suppl 5): 107 (Abstr 513).
147. Staab H-J, von Pawel J, Gatzemeier U et al. Topotecan in salvage therapy of small cell lung cancer (SCLC) after failure of first-line therapy. The sixth conference on DNA topoisomerases in therapy, Amsterdam, 6-8 September 1995 (Abstr 80).
148. Managold C, Pawal JV, Scheithauer W et al. Response of SCLC brain metastases to topotecan (SK&F 104864) therapy. Ann Oncol 1996; 7 (Suppl 5): 106 (Abstr 510).
149. Weitz JJ, Jung S-H, Marschke RF et al. Randomized phase II trial of two schedules of topotecan for the treatment of advanced stage non-small-cell lung carcinoma (NSCLC): A North Central Cancer Treatment Group (NCCTG) trial. Proc Am Soc Clin Oncol 1995; 14: 348 (Abstr 1053).
150. Perez-Soler R, Fossella FV, Glisson BS et al. Phase II study of topotecan in patients with advanced non-small-cell lung cancer previously untreated with chemotherapy. J Clin Oncol 1996; 14: 503-13.
151. Perez-Soler R, Khuri F, Pisters KM et al. Phase II study of topotecan in patients with squamous carcinoma of the lung previously untreated with chemotherapy. Proc Am Soc Clin Oncol 1997; 16: 450a (Abstr 1619).
152. Lynch TJ Jr, Kalish L, Strauss G et al. Phase II study of topotecan in metastatic non-small-cell lung cancer. J Clin Oncol 1994; 12: 347-52.
153. Robert F, Wheeler RH, Molthrop DC et al. Phase II study of topotecan in advanced head and neck cancer: Identification of an active new agent. Proc Am Soc Clin Oncol 1994; 13: 281 (Abstr 905).
154. Eisenhauer EA, Wainman N, Boos G et al. Phase II trials of topotecan in patients with malignant glioma and soft tissue sarcoma. Proc Am Soc Clin Oncol 1994; 13: 175 (Abstr 488).
155. Giantonio BJ, Kosierowski R, Ramsey SC et al. Phase II study of topotecan for hormone refractory prostate cancer (HRPC). Proc Am Soc Clin Oncol 1993; 12: 247 (Abstr 774).
156. Hudes GR, Kosierowski R, Greenberg R et al. Phase II study of topotecan in metastatic hormone-refractory prostate cancer. Invest New Drugs 1995; 13: 235-40.
157. MacDonald D, Cairncross G, Stewart D et al. Phase II study of topotecan in patients with recurrent malignant gliomas. Ann Oncol 1996; 7: 205-7.
158. Kyritsis A, Newlands ES, Brock CS et al. Phase II trial of topotecan as a continuous intravenous infusion in patients with high-grade gliomas. Proc Am Soc Clin Oncol 1997; 16: 394a (Abstr 1404).
159. O'Brian S, Kantarjian H, Ellis A et al. Topotecan in chronic lymphocytic leukemia. Cancer 1995; 75: 1104-8.
160. Law TM, Ilson DH, Motzer RJ. Phase II trial of topotecan in patients with advanced renal cell carcinoma. Invest New Drugs 1994; 12: 143-5.
161. Sugarman SM, Pazdur R, Daugherty K et al. A phase II trial of topotecan (TPT) for the treatment of unresectable pancreatic cancer (PC). Proc Am Soc Clin Oncol 1994; 13: 224 (Abstr 684).
162. Pue HS, Bajorin DF, Bosl GJ et al. Phase II trial of topotecan in patients with cisplatin-refractory germ cell tumours. Invest New Drugs 1995; 13: 163-5.
163. Witte RS, Propert KJ, Burch P et al. An ECOG phase II trial of topotecan in previously treated advanced urothelial carcinoma. Proc Am Soc Clin Oncol 1997; 16: 324a (Abstr 1153).
164. Chang AY, Garrow G, Boros L et al. Clinical and laboratory studies of topotecan in breast cancer. Proc Am Soc Clin Oncol 1995; 14: 105 (Abstr 118).
165. Goldschmidt E, Bonneterre J, Fumoleau P et al. A phase II study of topotecan on a daily × 5 schedule as second-line single agent therapy in patients with advanced breast cancer. Proc Am Soc Clin Oncol 1997; 16: 171a (Abstr 598).
166. Spaeth D, Bonneterre J, Marty M et al. Phase II studies of two trial regimens of topotecan as second-line single agent therapy in advanced breast cancer. Proc Am Soc Clin Oncol 1997; 16: 192a (Abstr 675).
167. Blaney SM, Phillips PC, Packer RJ et al. Phase II evaluation of topotecan for pediatric central nervous system tumours. Cancer 1996; 78: 527-31.
168. Sugarman SM, Ajani JA, Daugherty K et al. A Phase II trial of topotecan (TPT) for the treatment of advanced, measurable colorectal cancer. Proc Am Soc Clin Oncol 1994; 13: 225 (Abstr 686).
169. Creemers GJ, Wanders J, Gamucci T et al. Topotecan in colorectal cancer: A phase II study of the EORTC early clinical trials group. Ann Oncol 1995; 6: 844-6.
170. Hochster H, Ibrahim J, Liebes L et al. Phase II study of 21-day topotecan continuous infusion for metastatic colorectal cancer. Proc Am Soc Clin Oncol 1997; 16: 290a (Abstr 1032).
171. Creemers GJ, Gerrits CJH, Schellens JHM et al. Phase II and pharmacologic study of topotecan administered as a 21-day continuous infusion to patients with colorectal cancer. J Clin Oncol 1996; 14: 2540-5.
172. Verweij J, Topotecan, a review on a clinically active new cancer agent. The sixth conference on DNA topoisomerases in therapy. Amsterdam, 6-8 September 1995 (Abstr S66).
173. Janik J, Miller L, Smith J et al. Prechemotherapy granulocytemacrophage colony stimulating factor (GM-CSF) prevents topotecan-induced neutropenia. Proc Am Soc Clin Oncol 1993; 12: 437 (Abstr).
174. Maliepaard MJ, Loos WJ, Kolker HJ et al. Synergistic schedule dependent cytotoxicity of cisplatin and topotecan in human tumour cell lines. The sixth conference on DNA topoisomerases in therapy, Amsterdam, 6-8 September 1995 (Abstr 55).
175. Lilenbaum RC, Rosner GL, Ratain MJ et al. Phase I study of taxol and topotecan in patients with advanced solid tumours. Proc Am Soc Clin Oncol 1994; 13: 131 (Abstr 319).
176. Miller AA, Hargis JB, Fields S et al. Phase I study of topotecan and cisplatin in patients with advanced cancer. Proc Am Soc Clin Oncol 1993; 12: 399 (Abstr 1367).
177. Saltz L, Kanowitz J, Schwartz G et al. Phase I trial of cisplatin (CDDP) plus topotecan on a daily × 5 schedule in patients with advanced solid tumours. Proc Am Soc Clin Oncol 1995; 14: 475 (Abstr 1541).
178. Murren J, Fedele S, Anderson I et al. Phase I trial of cyclophosphamide (ctx) and topotecan (tpt) in refractory cancer. Proc Am Soc Clin Oncol 1995; 14: 475 (Abstr 1542).
179. Tolcher AW, O'Shaughnessy JA, Weiss RB et al. A phase I study of topotecan followed sequentially by doxorubicin in patients with advanced malignancies. Clin Cancer Res 1997; 3: 755-80.
180. Kuhn J, Rizzo J, Eckardt J et al. Phase I bioavailability study of oral topotecan. Proc Am Soc Clin Oncol 1995; 14: 474 (Abstr 1538).
181. Chang AY, Gu CZ, Keng P et al. Topotecan (T) and etoposide (E) inhibit radiation repair differently than potential lethal damage (PLD) repair or sublethal damage repair (SLD). Proc Am Assoc Cancer Res 1992; 33: 437 (Abstr 2609).
182. Eckardt JR, Burris HA, Von Hoff DD et al. Measurement of tumour topoisomerase I and II levels during the sequential administration of topotecan and etoposide. Proc Am Soc Clin Oncol 1994; 13: 358 (Abstr).
183. Mattern M, Hoffman G, McCabe F et al. Synergistic cell killing by ionizing radiation and topoisomerase I inhibitor topotecan (SK.&F 104864). Cancer Res 1991; 51: 5813-6.
184. Anzai H, Frost P, Abbruzzese JL. Synergistic cytotoxicity with combined inhibition of topoisomerase (Topo) I and II. Proc Am Assoc Cancer Res 1992; 33: 431 (Abstr).
185. Graham MV, Jahanzeb M, Dresler C et al. Preliminary results of a phase I study of topotecan plus thoracic radiotherapy for locally advanced non-small-cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 1994; 13: 340 (Abstr 1132).
186. Takimoto CH, Dahut W, Marino MT et al. Pharmacodynamics and pharmacokinetics of a 72-hour infusion of 9-aminocamptothecin in adult cancer patients. J Clin Oncol 1997; 15: 1492-501.
187. Goldwasser F, Valenti M, Torres R et al. Potentiation of cisplatin cytotoxicity by 9-aminocamptothecin. Clin Cancer Res 1996; 2: 687-93.
188. Rubin E, Wood V, Bharti A et al. A phase I and pharmacokinetic study of a new camptothecin derivative, 9-amino-camptothecin. Clin Cancer Res 1995; 1: 269-76.
189. Hochster H, Liebes L, Speyer J et al. Phase I and pharmacodynamic study of prolonged infusion 9-amino-camptothecin in two formulations. Proc Am Soc Clin Oncol 1997; 16: 201a (Abstr 704).
190. Pitot HC, Knost JA, Mahoney MR et al. A phase II trial of 9-amino-20(S)-camptothecin in previously untreated patients with measurable metastatic colorectal carcinoma. Proc Am Soc Clin Oncol 1997; 16: 303a (Abstr 1077).
191. Kraut EH, Balcerzak SP, O'Rourke M et al. Phase II trial of 9-aminocamptothecin in patients with refractory breast cancer Proc Am Soc Clin Oncol 1997; 16: 177a (Abstr 620).
192. Wilson WH, Elwood P, Little R et al. A phase II and doseescalation study of 9-amino-camptothecin +/- G-CSF in relapsed lymphoma. Proc Am Soc Clin Oncol 1997; 16: 39a (Abstr 139).
193. Emerson DL, Besterman JM, Brown HR et al. In vivo antitumour activity of two new seven-substituted water soluble camptothecin analogues. Cancer Res 1995; 55: 603-9.
194. O'Dwyer PJ, DeMaria D, Kaye SB et al. GG211: A novel synthetic camptothecin derivative. Proceedings of the Seventh Conference on DNA Topoisomerases in Therapy 1996; 7: 35 (Abstr 30).
195. Gerrits CJH, Creemers GJ, Schellens JHM et al. Phase I and pharmacological study of the new topoisomerase I inhibitor G1147211, using a daily × 5 intravenous administration. Br J Cancer 1996; 73: 744-50.
196. Heinrich B, Lehnert M, Cavalli F et al. on behalf of the EORTC-Early Clinical Studies Group and the EORTC New Drug Development Office. Phase II trial of GI 147211 in locally advanced or metastatic non-small-cell lung cancer: An EORTC-ECSG trial. Proc Am Soc Clin Oncol 1997; 16: 470a (Abstr 1690).
197. van Oosterom AT, Gore M, Calvert AH et al. on behalf of the EORTC Early Clinical Studies Group and EORTC New Drug Development Office. Activity of GW211 (GI 147211) in relapsed ovarian cancer, a phase II study. Proc Am Soc Clin Oncol 1997; 16: 349a (Abstr 1250).
198. Schellens JHM, Pritchard JF, Gerrites EJH et al. Absolute oral bioavailability of the topoisomerase I inhibitor GG211. The sixth conference on DNA topoisomerases in therapy, Amsterdam, 6-8 September 1995 (Abstr 87).
199. Tohgo A, Joto N, Minami M et al. DX-8951F, a water-soluble camptothecin analog, exhibits potent antitumor activity against human lung cancer cell-line PC-6 and its SN-38 resistant variant. The sixth conference on DNA topoisomerases in therapy, 1995 (Abstr 71).
200. Stehlin JS, Natelson EA, Hinz HR et al. Phase I clinical trial and pharmacokinetic results with oral administration of 20(S)-camptothecin. In Potmesil M, Pinedo HM (eds): Camptothecins: New Anticancer Agents. Boca Raton, FL: CRC Press 1995; 59-65.
201. Hinz HR, Harris NJ, Natelson EA, Giovanella BC. Pharmacokinetics of the in vivo and in vitro conversion of 9-nitro-20(S)-camptothecin to 9-amino-20(S)-camptothecin in humans, dogs, and mice. Cancer Res 1994; 54: 3096-100.
202. Natelson EA, Giovanella BC, Verschraegen CF et al. Phase I clinical and pharmacological studies of 20-(S)-camptothecin and 20-(S)-9-nitrocamptothecin as anticancer agents. In Pantazis P, Giovanella BC, Rothenberg ML (eds): The Camptothecins: From Discovery to the Patient. New York: Annals of the New York Academy of Sciences 1996; 804: 224-30.
203. Verschraegen C, Giovanella B, Armstrong K et al. Phase II study of oral administration of 9-nitrocamptothecin in refractory ovarian cancer. Proc Am Soc Clin Oncol 1997; 16: 381a (Abstr 1356).
204. Pommier Y, Gupta M, Valenti M, Nieves-Neira W. Cellular resistance to Camptothecins. In Pantazis P, Giovanella BC, Rothenberg ML (eds): The Camptothecins: From Discovery to the Patient. New York: Annals of the New York Academy of Sciences 1996; 803: 60-73.
205. Kohno K, Sato S-I, Uchiumi T et al. Activation of the human multidrug resistance 1 (MDR1) gene promoter in response to inhibitors of DNA topoisomerases. Int J Oncol 1992; 1: 73-7.
206. Hendricks CB, Rowinsky EK, Grochow LB et al. Effect of p-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue. Cancer Res 1992; 52: 2268-78.
207. Yang C-HJ, Horton JK, Cowan KH, Schneider E. Cross-resistance to camptothecin analogues in a mitoxantrone-resistant human breast carcinoma cell line is not due to DNA topoisomerase I alterations. Cancer Res 1995; 55: 4004-9.
208. Eng WK, McCabe FL, Tan KB et al. Development of a stable camptothecin-resistant subline of P388 leukaemia with reduced topoisomerase I content. Mol Pharmacol 1990; 38: 471-80.
209. Kanzawa F, Sugimoto Y, Minato K et al. Establishment of a camptothecin analogue (CPT-11)-resistant cell line of human non-small-cell lung cancer: Characterization and mechanism of resistance. Cancer Res 1990; 50: 5919-24.
210. Kaufmann SH, Rowinsky EK, Gore SD et al. Factors affecting topotecan sensitivity in human leukaemia samples. Proceedings of the Seventh Conference on DNA Topoisomerases in Therapy 1996; 7: 36 (Abstr 36).
211. Beidler DR, Cheng YC. Camptothecin induction of a time- and concentration-dependent decrease of topoisomerase I and its implication in camptothecin activity. Mol Pharmacol 1995; 47: 907-14.
212. Murren JR, Fedele J, Anderson S et al. Topotecan induces rapid decrease in intracellular topoisomerase I concentration in peripheral blood mononuclear cells. Proc Am Assoc Cancer Res 1995; 36: 242 (Abstr 1440).
213. Hochster H, Liebes L, Zelenuch-Jacquotte A et al. Pharmacodynamics of topo-I depletion in peripheral-blood mononuclear cells: A phase II study of second-line topotecan in patients with ovarian cancer. Proceedings of the Seventh Conference on DNA Topoisomerases in Therapy 1996; 7: 36 (Abstr 34).
214. Eckardt JR, Burris HA, Von Hoff DD et al. Measurement of tumour topoisomerase I and II levels during the sequential administration of topotecan and etoposide. Proc Am Soc Clin Oncol 1995; 13: 141 (Abstr 358).
215. Saleem A, Toppmeyer D, Gupta E et al. Analysis of topoisomerase I and II protein levels in a clinical trial of sequential camptothecin and etoposide. Proceedings of the Seventh Conference on DNA Topoisomerases in Therapy 1996; 7: 37 (Abstr 37).
216. OhiraT, Nishio K, Kanzawa F et al. Hypersensitivity of NIH3T3 cells transformed by H-ras to DNA-topoisomerase-I inhibitors. Int J Cancer 1996; 67: 702-8.
217. Danks MK, Garrett KE, Marion RC et al. Subcellular redistribution of DNA topoisomerase I in anaplastic astrocytoma cells treated with topotecan. Cancer Res 1996; 56: 1664-73.
218. Buckwalter CA, Lin AH, Tanizawa A et al. RNA synthesis inhibitors alter the subnuclear distribution of DNA topoisomerase I. Cancer Res 1996; 56: 1674-81.
219. Tamura H, Kohchi C, Yamada R et al. Molecular cloning of a cDNA of a camptothecin-resistant human DNA topoisomerase-I and identification of mutation sites. Nucleic Acids Res 1990; 19: 69-75.
220. Rubin E, Pantazis P, Bharti A et al. Identification of a mutant topoisomerase I with intact catalytic activity and resistance to 9-nitro-camptothecin. J Biol Chem 1994; 269: 2433-9.
221. Niimi S, Nakagawa K, Sugimoto Y et al. Mechanism of cross-resistance to a camptothecin analogue (CPT-11) in a human ovarian cancer cell line selected by cisplatin. Cancer Res 1992; 52: 328-33.
222. Chen SF, Rothenberg ML, Clark G et al. Human tumour carboxylesterase activity correlates with CPT-11 cytotoxicity in vitro. Proc Am Assoc Cancer Res 1994; 35: 365 (Abstr 2174).
223. Zwelling LA, Slovak ML, Doroshow JH et al. Ht1080/DR4: A p-glycoprotein-negative human fibrosarcoma cell line exhibiting resistance to topoisomerase-II-reactive drugs despite the presence of a drug-sensitive topoisomerase II. J Natl Cancer Inst 1990; 82: 1553-61.
224. Kaufmann S. Inhibition of topoisomerase II-mediated cytotoxicity in a human leukemia cell line by camptothecin and other inhibitors of RNA synthesis. 3rd Conference on DNA Topoisomerases in Therapy 1990: 37 (Abstr).
225. Jones C, Clements M, Wasi S, Daoud SS. Synergy between UCN-01 and camptothecin-induced cytotoxicity in human breast cancer cells. Proc Am Assoc Cancer Res 1997; 38: 16 (Abstr 102).
226. Shao RG, Shimizu T, Pommier Y. Poetentiation of camptothecin cytotoxicity in p53 mutant HT-29 cells by UCN-01, an abrogator of the S and G2 checkpoints. Proc Am Assoc Cancer Res 1997; 38: 439 (Abstr 2938).
227. Cao CX, Shao RG, Pommier Y. Upregulation of PKC-alpha is associated with apoptosis induced by 7-hydroxystaurosporine and camptothecin in human leukemia HL60 cells. Proc Am Assoc Cancer Res 1997; 38: 501 (Abstr 3360).
228. Kohn KW. Events downstream of the topoisomerase-DNA lesions: How might cancer cells be killed selectively? Proceedings of the Seventh Conference on DNA Topoisomerases in Therapy 1996; 7: 37 (Abstr 40).
229. Pommier Y, Goldwasser F, Shimuzu T et al. Studies of apoptosis and cell cycle arrest produced by topoisomerase I blockers. Proceedings of the Seventh Conference on DNA Topoisomerases in Therapy 1996; 7: 38 (Abstr 44).
230. Nieves-Neira W, Pommier Y. Differential apoptotic response and lack of correlation between apoptosis and camptothecin toxicity in breast cancer cell lines of the NCI Anticancer Drug Screen. Proceedings of the Seventh Conference on DNA Topoisomerases in Therapy 1996; 7: 50 (Abstr P37).
231. Solary E, Bertrand R, Pommier Y. Apoptosis induced by DNA topoisomerase I and II inhibitors in human leukemic HL-60 cells. Leuk Lymph 1994; 15: 21-32.
232. Shimizu T, Pommier Y. DNA fragmentation induced by protease activation in p53-null human leukemia cells undergoing apoptosis following treatment with the topoisomerase I inhibitor camptothecin: Cell-free system studies. Exp Cell Res 1996; 226: 292-301.
233. Tishler RB, Calderwood SK, Coleman CN et al. Increases in sequence-specific DNA binding by p53 following treatment with chemotherapeutic and DNA-damaging agents. Cancer Res 1993; 53: 2212-6.
234. Yamashita Y, Kawada S, Fujii N et al. Induction of mammalian topoisomerase I and II mediated DNA cleavage by saintopin, a new antitumor agent from fungus. Biochemistry 1991; 30: 5838-45.
235. Taniguchi K, Kohno K, Kawanami K et al. Drug-induced down-regulation of topoisomerase I in human epidermoid cancer cells resistant to saintopin and camptothecins. Cancer Res 1996; 56: 2348-54.
236. Horiguchi T, Hayashi K, Tsubotani S et al. New naphthacene-carboxamide antibiotics, TAN-1518 A and B, have inhibitory activity against mammalian DNA topoisomerase I. J Antibiot (Tokyo) 1994; 47: 545-56.
237. Andoh T, Ohtsuki S, Oshimi Y et al. Mode of action and mechanism of resistance to a novel topoisomerase I inhibitor TAN-15I8A. Proceedings of the Seventh Conference on DNA Topoisomerases in Therapy 1996; 7: 29 (Abstr 08).
238. Yamashita Y, Fujii N, Murakata C et al. Induction of mammalian DNA topoisomerase I-mediated DNA cleavage by antitumor indolocarbazole derivatives. Biochemistry 1992; 31: 12069-75.
239. Yoshinari T, Yamada A, Uemura D et al. Induction of topoisomerase I -mediated DNA cleavage by a new indolocarbazole, ED-110. Cancer Res 1993; 53: 490-4.
240. Yoshinari T, Matsumoto M, Arkawa H et al. Novel antitumor indolocarbazole compound 6-N-formylamino-12, 13-dihydro-1, 11- dihydroxy-13- (beta-D-glucopyranosyl)-5H-indolo(2, 3-a) pyrrolo(3, 4- c) carbazole-5, 7 (6H)-dione (NB-506): Induction of topoisomerase I-mediated DNA cleavage and mechanisms of cell line-selective cytotoxicity. Cancer Res 1995; 55: 1310-5.
241. Fujii N, Yamashita Y, Saitoh Y et al. The induction of mammalian DNA topoisomerase I-mediated DNA cleavage and DNA winding by bulgarein. J Biol Chem 1993; 268: 13160-5.
242. Chen AY, Yu C, Gatto B et al. DNA minor groove-binding ligands: A different class of mammalian DNA topoisomerase I inhibitors. Proc Nat Acad Sci USA 1993; 90: 8131-5.
243. Yamashita Y, Fujii N, Nakano H. Identification of novel topoisomerase I inhibitors. Proc Am Assoc Cancer Res 1994; 35: 707.
244. Larsen AK, Grondard L, Couprie J et al. The antileukemic alkaloid fagaronine is an inhibitor of DNA topoisomerases I and II. Biochem Pharmacol 1993; 46: 1403-12.
245. Gatto B, Sanders MM, Yu C et al. Identification of topoisomerase I as the cytotoxic target of the protoberberine alkaloid coralyne. Cancer Res 1996; 56: 2795-800.
246. Li CJ, Averboukh L, Pardee AB. Beta-Lapachone, a novel DNA topoisomerase I inhibitor with a mode of action different from camptothecin. J Biol Chem 1993; 268: 22463-8.
247. Liu SY, Lee YW, Han FS et al. Identification of novel inhibitor of human DNA topoisomerase I and II from Chinese herb medicine. Proc Am Assoc Cancer Res 1990; 31: (Abstr 2603).
248. Zanier R, De Salvia R, Fiore M et al. Topoisomerase I activity and cellular reponse to radiation in Chinese Hamster cells. Int J Radiat Biol 1996; 70: 251-9.
249. Marchesini R, Colombo A, Caserini C et al. Interaction of ionizing radiation with topotecan in two human cell lines. Int J Cancer 1996; 66: 342-6.